We could not find any results for:
Make sure your spelling is correct or try broadening your search.
HIGHLIGHTS First human dosing of PlexarisTM has occurred in Exopharm’s PLEXOVAL Study PLEXOVAL is a world-first study using a cell free, platelet-derived exosome product manufactured using...
A leading developer of exosome therapies, Australia-based Exopharm Limited, supports the US Food & Drug Administration (FDA) in highlighting the health dangers of unapproved products peddled...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | -0.419 | -97.4418604651 | 0.43 | 0.485 | 0.008 | 591268 | 0.04756751 | DE |
260 | -0.269 | -96.0714285714 | 0.28 | 1 | 0.008 | 444409 | 0.25389022 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions